Cencora (COR) to Release Q1 Fiscal 2026 Results on February 4, 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1d ago
0mins
Source: Businesswire
- Earnings Release Schedule: Cencora plans to release its Q1 Fiscal 2026 results on February 4, 2026, prior to NYSE opening, which is expected to provide investors with the latest insights into the company's performance.
- Conference Call Details: The company will host a conference call at 8:30 a.m. ET on the same day, led by CEO Robert P. Mauch and CFO James F. Cleary, aimed at analyzing financial results and addressing investor inquiries.
- Webcast Information: The call will be webcast via the company's website, with users encouraged to log on 10 minutes early, reflecting the company's commitment to transparency and investor communication.
- Replay Services: A replay of the call will be available via webcast and telephone approximately one hour after the call, with the webcast accessible for one year and the telephonic replay for seven days, ensuring that investors unable to attend live can still access key information.
Analyst Views on COR
Wall Street analysts forecast COR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for COR is 393.78 USD with a low forecast of 361.00 USD and a high forecast of 417.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
9 Buy
1 Hold
0 Sell
Strong Buy
Current: 346.170
Low
361.00
Averages
393.78
High
417.00
Current: 346.170
Low
361.00
Averages
393.78
High
417.00
About COR
Cencora, Inc. is a global pharmaceutical sourcing and distribution services company. The Company helps both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The Company operates through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. Healthcare Solutions segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, long-term care and alternate site pharmacies, and other customers. The International Healthcare Solutions segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
